

Tuberculosis profile: Nepal

Population 2019: 29 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	68 000 (40 000-103 000)	238 (141-359)
HIV-positive TB incidence	490 (280-750)	1.7 (1-2.6)
MDR/RR-TB incidence**	2 200 (890-4 000)	7.6 (3.1-14)
HIV-negative TB mortality	17 000 (9 100-26 000)	58 (32-92)
HIV-positive TB mortality	220 (130-340)	0.77 (0.45-1.2)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	2.2% (1.1-3.6)
Previously treated cases	15% (9.6-22)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	46% (31-78)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	26% (11-45)

TB case notifications, 2019

Total new and relapse	31 495
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	70%
- % pulmonary	71%
- % bacteriologically confirmed ^	82%
- % children aged 0-14 years	6%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	34%
- % men	60%
Total cases notified	32 043

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	159	0.72%
- on antiretroviral therapy	155	97%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	80%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	85%
Laboratory-confirmed cases - MDR/RR-TB ^^	635
Patients started on treatment - MDR/RR-TB ^^	378
Laboratory-confirmed cases - XDR-TB ^^	29
Patients started on treatment - XDR-TB ^^	14
MDR/RR-TB cases tested for resistance to any fluoroquinolone	417

Treatment success rate and cohort size


	Success	Cohort
New cases registered in 2018	91%	28 967
Previously treated cases registered in 2018	88%	3 346
HIV-positive TB cases registered in 2018	79%	125
MDR/RR-TB cases started on second-line treatment in 2017	70%	328
XDR-TB cases started on second-line treatment in 2017	88%	16

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	37% (34-41)



Treatment success rate



Total budget



TB financing

National TB budget, 2020 (US\$ millions)	24
- Funding source, domestic	31%
- Funding source, international	38%
- unfunded	31%

* *Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.*

** *MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin*

^ *Calculated for pulmonary cases only*

^^ *Includes cases with unknown previous TB treatment history*

^^^ *Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed*

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)